US-Chi­na ten­sions threat­en to en­snare ad­di­tion­al Chi­nese bio­phar­ma con­trac­tors

In re­cent weeks, pro­posed fed­er­al leg­is­la­tion has forced US drug­mak­ers to re­think their re­la­tion­ship with a Chi­nese com­pa­ny that’s a sta­ple in drug de­vel­op­ment. Now, the in­dus­try is start­ing to wake up to the po­ten­tial for re­stric­tions on ad­di­tion­al Chi­nese biotech con­trac­tors.

The Biose­cure Act threat­ens to black­list WuXi AppTec and oth­er “com­pa­nies of con­cern” from do­ing busi­ness in the US. But less known is that the bill could ex­pand to tar­get ad­di­tion­al Chi­nese firms, in­clud­ing con­trac­tors like Bei­jing-head­quar­tered Phar­maron, which is the sec­ond-biggest con­tract re­search or­ga­ni­za­tion af­ter WuXi; and syn­thet­ic DNA com­pa­ny Gen­Script, whose cus­tom man­u­fac­tur­ing ser­vices are based in Nan­jing, Chi­na.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER